While the demand for discovery and development of novel therapies to address drug-resistant infections has been clearly elucidated again and again, the big biopharmaceutical industry players continue to pull out – but it remains to be seen whether new efforts to drive early-stage R&D can fill the gap.
Despite regulatory incentives like the GAIN (Generating Antibiotic Incentives Now) provisions the US FDA introduced in 2012, the antimicrobial resistance...